Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fisher

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
Science Translational Medicine|May 31, 2023
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomasNobuhiko Kanaya, Yohei Kitamura, Maria Lopez Vazquez, et al.
Clinical Trials (London, England)|January 27, 2022
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancerLouise C Brown, Janet Graham, David Fisher, et al.
Journal of Medical Genetics|March 12, 2017
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximabAyman Madi, David Fisher, Timothy S Maughan, et al.
Cancer Treatment Reviews|June 15, 2021
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysisRichard Adams, Kaitlyn Goey, Benoist Chibaudel, et al.
British Journal of Cancer|July 13, 2021
Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backboneSanne Ten Hoorn, Dirkje W Sommeijer, Faye Elliott, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Lancet (London, England)|October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataClaire L Vale, David Fisher, Andrew Kneebone, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
Science Translational Medicine|May 31, 2023
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomasNobuhiko Kanaya, Yohei Kitamura, Maria Lopez Vazquez, et al.
Clinical Trials (London, England)|January 27, 2022
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancerLouise C Brown, Janet Graham, David Fisher, et al.
Journal of Medical Genetics|March 12, 2017
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximabAyman Madi, David Fisher, Timothy S Maughan, et al.
Cancer Treatment Reviews|June 15, 2021
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysisRichard Adams, Kaitlyn Goey, Benoist Chibaudel, et al.
British Journal of Cancer|July 13, 2021
Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backboneSanne Ten Hoorn, Dirkje W Sommeijer, Faye Elliott, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
The Lancet. Oncology|January 1, 2016
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate dataClaire L Vale, Sarah Burdett, Larysa H M Rydzewska, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trialsAlessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
Lancet (London, England)|October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataClaire L Vale, David Fisher, Andrew Kneebone, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJennifer L Crombie, Austin I Kim, Robert Redd, et al.
Pageof 19